Posterior reversible encephalopathy syndrome (PRES) and myeloma
Ricardos Ghanem1, Sylvie Glaisner2, Arthur Bobin3
1Centre Hospitalier Sud Francilien, Hématologie clinique, Corbeil-Essonnes, France.
Abstract:
Posterior reversible encephalopathy syndrome (PRES) has rarely been described in myeloma, but chemotherapy is a known risk factor. We report 3 patients with myeloma who developed PRES, and analyzed them with 13 published cases, mostly women. The most frequent causative agents were proteasome inhibitors and autologous stem cell transplantation. Risk factors were frequently associated: hypertension, infection or renal failure. Symptoms included headache, blurred vision, altered mental status, seizures. Most patients experienced rapid clinical recovery, without relapse even after resuming treatment. Although rare, we must remain vigilant about PRES in myeloma patients. Stricter control of blood pressure could limit its occurrence.


